Loading...

Company profile

Beacon Pharma sees steady growth

FE REPORT | Published: September 22, 2019 11:11:16 | Updated: September 23, 2019 11:15:23


Beacon Pharmaceuticals, one of the leading pharmaceutical companies, has displayed a steady growth for last five years in its financial indicators, including net profits.

The company's earnings per share (EPS), net asset value (NAV), and net profits rose gradually since 2014 to 2018.

The company, however, is yet to disclose its financial statement for the year ended on June 30, 2019.

The company reported its EPS of Tk 0.10 for 2014, Tk 015 for 2015, Tk 0.27 for 2016, Tk 0.45 for 2017 and Tk 0.55 for 2018.

The company's net asset value (NAV) per share was Tk 12.41 in 2014, Tk 12.58 in 2015, Tk 13 in 2016, Tk 13.37 in 2017 and Tk 12.99 in 2018.

The company also reported its EPS of Tk. 0.21 for January-March 2019 as against Tk. 0.14 for January-March 2018. The net operating cash flow per share (NOCFPS) was Tk. 0.79 for July 2018-March 2019 as against Tk. 1.97 for July 2017-March 2018.

The company displayed a steady growth in return on assets (ROA) during 2014 to 2018.

The ROA, which is displayed as a percentage, is an indicator of a company's profitability relative to its total assets. This ratio gives an idea as to how efficient a company's management is at using its assets to generate earnings.

The ROA of Beacon Pharmaceuticals was 0.52 per cent in 2014, 0.81 per cent in 2015, 1.22 per cent in 2016, 2.03 per cent in 2017, and 2.57 per cent in 2018.

The company's return on equity (ROE) also rose gradually since 2014 t0 2018.

The ROE is considered a measure of how effectively management is using a company's assets to create profits.

The ROE of Beacon Pharmaceuticals was 0.85 per cent in 2014, 1.33 per cent in 2015, 2.04 per cent in 2016, 3.47 per cent in 2017 and 4.20 per cent in 2018.

"Our loyal and dedicated employees have tried to overcome most of the adverse situations and presented a reasonable growth result with a commitment for the better in future," Nurun Nahar Karim, the chairman of Beacon Pharmaceuticals, said in her message included in the annual report for 2018.

The company's revenues rose gradually since 2014 to 2015. Its revenue was Tk 1.69 billion in 2014, Tk 2.05 billion in 2015, Tk 2.49 billion in 2016, Tk 2.94 billion in 2017 and Tk 3.76 billion in 2018.

Following the gradual growth in revenue earnings, the company's net profit also displayed a steady growth in net profits.

The net profit of Beacon Pharmaceuticals was Tk 24.22 million in 2014, Tk 38.55 million in 2015, Tk 61.40 million in 2016, Tk 103.73 million in 2017 and Tk 126.10 million in 2018.

Beacon Pharmaceuticals was listed with the stock exchanges in 2010. Its paid-up capital is Tk 2.31 billion.

The company's sponsor-directors hold 30 per cent shares, institutes 21.82 per cent and general public 48.18 per cent as of August 31, 2019.

The company's share price closed at Tk 25 each on Thursday with a marginal loss of 1.16 per cent or Tk 0.3 on Dhaka Stock Exchange (DSE).

mufazzal.fe@gmail.com

Share if you like